开始使用维多珠单抗不会引起炎症性肠病患者新发脊柱关节炎：一项为期 24 周的前瞻性影像学评估研究。
Initiation of vedolizumab did not provoke new-onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24-week study with imaging assessments.
发表日期：2024 Jul 04
作者：
Sherry Rohekar, Tristan Boyd, Robert G Lambert, Melanie Beaton, Nilesh Chande, Jamie Gregor, Heather Lennox, Keith Mcintosh, Terry Ponich, Adam Rahman, Trimadhu Sharma, Michael Sey, Maria Tauqir, Vipul Jairath
来源：
ARTHRITIS RESEARCH & THERAPY
摘要：
维多珠单抗与新发脊柱关节炎 (SpA) 之间存在时间关系。我们通过系列临床评估和磁共振成像 (MRI) 评估了炎症性肠病 (IBD) 患者开始使用维多珠单抗与新发 SpA 发展之间的关系). 一项针对 24 名 IBD 患者的单中心前瞻性观察研究。如果患者患有活动性溃疡性结肠炎或克罗恩病 (CD)、正在开始使用维多珠单抗、既往没有关节炎或 SpA 病史并且适合进行系列 MRI，则符合资格。风湿病学家在第一次给药前以及第 8 周和第 24 周进行了临床评估。轴向 MRI 由盲法中心阅读器进行评估，并在基线第 8 周和第 24 周进行。 9 名未接受过肿瘤坏死因子 (TNF) 抑制剂治疗的患者（4 名男性；平均年龄 53.2 岁；6 名 UC；3 名 CD）和 8 名接受过 TNF 抑制剂治疗的患者患者（7 名男性；平均年龄 48 岁；3 名 UC；5 名 CD）完成了所有评估。没有患者出现中轴关节炎的新特征或外周 SpA 的特征（炎性寡关节炎、附着点炎、指趾炎或牛皮癣（指甲、身体或头皮））。两组均表现出良好的肠道反应。在使用过 TNF 抑制剂或未使用过 TNF 抑制剂的 IBD 患者中，治疗 24 周后，维多珠单抗起始治疗并未诱发中轴或外周 SpA 的新特征。© 2024 作者。 《联合欧洲胃肠病学杂志》由 Wiley periodicals LLC 代表联合欧洲胃肠病学出版。
A temporal relationship between vedolizumab and new-onset spondyloarthritis (SpA) has been suggested.We evaluated the relationship between vedolizumab initiation and development of new-onset SpA in patients with inflammatory bowel disease (IBD) through serial clinical evaluation and magnetic resonance imaging (MRI).A single-centre prospective observational study of 24 patients with IBD. Patients were eligible if they had active ulcerative colitis or Crohn's disease (CD), were initiating vedolizumab, had no prior history of arthritis or SpA and were suitable for serial MRI. A rheumatologist performed clinical evaluation prior to the first dose and 8 and 24 weeks. Axial MRI was evaluated by a blinded central reader and performed at baseline 8 and 24 weeks.Nine tumor necrosis factor (TNF) inhibitor-naïve patients (4 male; mean age 53.2 years; 6 UC; 3 CD) and eight TNF inhibitor-experienced patients (7 male; mean age 48 years; 3 UC; 5 CD) completed all assessments. No patients developed new features of axial arthritis or features of peripheral SpA (inflammatory oligoarthritis, enthesitis, dactylitis, or psoriasis (nail, body, or scalp)). Both groups demonstrated a good intestinal response.Vedolizumab initiation did not induce new features of axial or peripheral SpA after 24 weeks of treatment in TNF inhibitor-experienced or TNF inhibitor-naive patients with IBD.© 2024 The Author(s). United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.